Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,272 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Regulatory
500 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Abemaciclib | EU EMA | Malignant Breast Neoplasm | Early Breast Cancer Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1). In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. Advanced or Metastatic Breast Cancer Verzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. | approved | Sep 26, 2018 | ema |
| Abemaciclib | US FDA | Malignant Breast Neoplasm | as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. | approved | Sep 28, 2017 | openfda |
| Abemaciclib | US FDA | Malignant Breast Neoplasm | in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Data updated 20 hours agoSource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Cetuximab | 401 | 91 | 309 |
| Dasatinib | 307 | 174 | 133 |
| Erlotinib | 266 | 172 | 94 |
| Crizotinib | 255 | 135 | 120 |
| Vemurafenib | 252 | 141 | 110 |
| Gefitinib | 185 | 142 | 43 |
| Imatinib | 165 | 73 | 92 |
| Trametinib | 149 | 123 | 26 |
| Afatinib | 129 | 120 | 9 |
| Panitumumab | 127 | 34 | 93 |
| Trastuzumab | 127 | 90 | 37 |
| Dabrafenib | 105 | 72 | 33 |
| Olaparib | 105 |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| approved |
| Sep 28, 2017 |
| openfda |
| Abemaciclib | US FDA | Malignant Breast Neoplasm | in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. | approved | Sep 28, 2017 | openfda |
| Abemaciclib | US FDA | Malignant Breast Neoplasm | in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. | approved | Sep 28, 2017 | openfda |
| Abiraterone | EU EMA | Castration-Resistant Prostate Carcinoma | Abiraterone Accord is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. | approved | Apr 26, 2021 | ema |
| Abiraterone | EU EMA | Castration-Resistant Prostate Carcinoma | Zytiga is indicated with prednisone or prednisolone for: the treatment of metastatic castration resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated the treatment of metastatic castration resistant prostate cancer in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.accelerated | approved | Sep 5, 2011 | ema |
| Abiraterone | US FDA | Castration-Resistant Prostate Carcinoma | Abiraterone Acetate is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone Acetate is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) | approved | May 22, 2018 | openfda |
| Abiraterone Acetate | EU EMA | Malignant Prostate Neoplasm | Treatment of adult patients with prostate cancer. | approved | Apr 19, 2023 | ema |
| Abiraterone Acetate | EU EMA | Castration-Resistant Prostate Carcinoma | Abiraterone Mylan is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT). the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. | approved | Aug 20, 2021 | ema |
| Abiraterone Acetate | EU EMA | Castration-Resistant Prostate Carcinoma | Abiraterone Krka is indicated with prednisone or prednisolone for: the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1) the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1) the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. | approved | Jun 24, 2021 | ema |
| Abiraterone Acetate | US FDA | Castration-Resistant Prostate Carcinoma | Abiraterone Acetate is indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone Acetate is a CYP17 inhibitor indicated in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1 ) | approved | May 22, 2018 | openfda |
| Acalabrutinib | US FDA | Mantle Cell Lymphoma | In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). | approved | Aug 3, 2022 | openfda |
| Acalabrutinib | US FDA | Mantle Cell Lymphoma | In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). | approved | Aug 3, 2022 | openfda |
| Acalabrutinib | US FDA | Mantle Cell Lymphoma | In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). | approved | Oct 31, 2017 | openfda |
| Adagrasib | EU EMA | Lung Non-Small Cell Carcinoma | Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.conditional | approved | Jan 5, 2024 | ema |
| Adagrasib | US FDA | Lung Non-Small Cell Carcinoma | Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. | approved | Dec 12, 2022 | openfda |
| Adagrasib | US FDA | Malignant Colorectal Neoplasm | Colorectal cancer (CRC)* • In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. | approved | Dec 12, 2022 | openfda |
| Afatinib | EU EMA | Lung Non-Small Cell Carcinoma | Giotrif as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. | approved | Sep 25, 2013 | ema |
| Afatinib | US FDA | Lung Non-Small Cell Carcinoma | Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy | approved | Jul 12, 2013 | openfda |
| Afatinib | US FDA | Lung Non-Small Cell Carcinoma | First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test | approved | Jul 12, 2013 | openfda |
| Aflibercept | EU EMA | Malignant Colorectal Neoplasm | Treatment of metastatic colorectal cancer (MCRC). | approved | Feb 1, 2013 | ema |
| Aflibercept | US FDA | Malignant Colorectal Neoplasm | ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. ZALTRAP, a vascular endothelial growth factor inhibitor, in combination with fluorouracil, leucovorin, irinotecan (FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. ( 1 ) | approved | Aug 3, 2012 | openfda |
| Aldesleukin | US FDA | Melanoma | The treatment of adults with metastatic melanoma. | approved | May 5, 1992 | openfda |
| Aldesleukin | US FDA | Renal Cell Carcinoma | The treatment of adults with metastatic renal cell carcinoma. | approved | May 5, 1992 | openfda |
| Alectinib | EU EMA | ALK-Positive Lung Non-Small Cell Carcinoma | Adjuvant treatment of resected non small cell lung cancer (NSCLC) Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK positive NSCLC at high risk of recurrence (see section 5.1 for selection criteria).Treatment of advanced NSCLCAlecensa as monotherapy is indicated for the first line treatment of adult patients with ALK positive advanced NSCLC.Alecensa as monotherapy is indicated for the treatment of adult patients with ALK positive advanced NSCLC previously treated with crizotinib. | approved | Feb 16, 2017 | ema |
| Alectinib | US FDA | Lung Non-Small Cell Carcinoma | treatment of adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test. | approved | Dec 11, 2015 | openfda |
| Alemtuzumab | EU EMA | Chronic Lymphocytic Leukemia | MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate. | withdrawnsince Aug 8, 2012 | Jul 6, 2001 | ema |
| Alemtuzumab | US FDA | Chronic Lymphocytic Leukemia | CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). CAMPATH is a CD52-directed cytolytic antibody indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). ( 1 ) | approved | May 7, 2001 | openfda |
| Alitretinoin | EU EMA | AIDS-Related Kaposi Sarcoma | Panretin gel is indicated for the topical treatment of cutaneous lesions in patients with acquired-immune-deficiency-syndrome (AIDS)-related Kaposi's sarcoma (KS) when: lesions are not ulcerated or lymphoedematous, and; treatment of visceral KS is not required, and; lesions are not responding to systemic antiretroviral therapy, and; radiotherapy or chemotherapy are not appropriate. | withdrawn | Oct 11, 2000 | ema |
| Alitretinoin | US FDA | AIDS-Related Kaposi Sarcoma | Kaposi’s Sarcoma PANRETIN GEL is indicated for topical treatment of cutaneous lesions in adults with AIDS related Kaposi’s sarcoma (KS). Limitations of Use: PANRETIN GEL is not indicated when systemic anti-KS therapy is required (including more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement) [see Clinical Studies ( 14.1 )] . PANRETIN GEL is a retinoid indicated for the topical treatment of cutaneous lesions in adults with AIDS-related Kaposi’s sarcoma (KS). Limitations of Use : PANRETIN GEL is not indicated when systemic anti-Kaposi’s sarcoma therapy is required. | approved | Feb 2, 1999 | openfda |
| Alpelisib | EU EMA | Malignant Breast Neoplasm | Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following an endocrine-based regimen (see section 5.1 and for biomarker-based patient selection see section 4.2). | approved | Jul 27, 2020 | ema |
| Alpelisib | US FDA | Malignant Breast Neoplasm | PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. PIQRAY is a kinase inhibitor indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. | approved | May 24, 2019 | openfda |
| Amivantamab | EU EMA | Lung Non-Small Cell Carcinoma | Rybrevant is indicated: in combination with lazertinib for the first line treatment of adult patients with advanced non small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations. in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced NSCLC with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI). in combination with carboplatin and pemetrexed for the first line treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations. as monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum based therapy. | approved | Dec 9, 2021 | ema |
| Amivantamab | US FDA | Lung Non-Small Cell Carcinoma | Previously Treated NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT, in combination with carboplatin and pemetrexed, is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor [see Dosage and Administration (2.2) ] . | approved | May 21, 2021 | openfda |
| Amivantamab | US FDA | Lung Non-Small Cell Carcinoma | First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT, in combination with carboplatin and pemetrexed, is indicated for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . | approved | May 21, 2021 | openfda |
| Amivantamab | US FDA | Lung Non-Small Cell Carcinoma | Previously Treated NSCLC with EGFR Exon 20 Insertion Mutations RYBREVANT is indicated as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] , whose disease has progressed on or after platinum-based chemotherapy. | approved | May 21, 2021 | openfda |
| Amivantamab | US FDA | Lung Non-Small Cell Carcinoma | First-Line Treatment of NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations RYBREVANT, in combination with lazertinib, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.2) ] . | approved | May 21, 2021 | openfda |
| Anagrelide | US FDA | Myeloproliferative Neoplasm | AGRYLIN is indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. AGRYLIN is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. ( 1 ) | approved | Mar 14, 1997 | openfda |
| Anastrozole | US FDA | Malignant Breast Neoplasm | Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to ARIMIDEX | approved | Dec 27, 1995 | openfda |
| Anastrozole | US FDA | Malignant Breast Neoplasm | First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer | approved | Dec 27, 1995 | openfda |
| Anastrozole | US FDA | Malignant Breast Neoplasm | Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer | approved | Dec 27, 1995 | openfda |
| Apalutamide | EU EMA | Nonmetastatic Castration-Resistant Prostate Carcinoma | Erleada is indicated: in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). | approved | Jan 14, 2019 | ema |
| Apalutamide | US FDA | Nonmetastatic Castration-Resistant Prostate Carcinoma | ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. ( 1 ) non-metastatic castration-resistant prostate cancer. ( 1 ) | approved | Feb 14, 2018 | openfda |
| Arsenic Trioxide | EU EMA | Acute Promyelocytic Leukemia | Arsenic trioxide medac is indicated for induction of remission, and consolidation in adult patients with: Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 10³/?l) in combination with all-trans-retinoic acid (ATRA) Relapsed/refractory APL (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the pro-myelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR?) gene. The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined. | approved | Sep 17, 2020 | ema |
| Arsenic Trioxide | EU EMA | Acute Promyelocytic Leukemia | Arsenic trioxide Mylan is indicated for induction of remission, and consolidation in adult patients with:- Newly diagnosed low to intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 103/?l) in combination with all trans retinoic acid (ATRA)- Relapsed/refractory acute promyelocytic leukaemia (APL) (Previous treatment should have included a retinoid and chemotherapy)characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic acid receptor alpha (PML/RAR alpha) gene. The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not beenexamined. | withdrawnsince Apr 14, 2025 | Apr 1, 2020 | ema |
| Arsenic Trioxide | EU EMA | Acute Promyelocytic Leukemia | Arsenic trioxide is indicated for induction of remission, and consolidation in adult patients with: Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 103/?l) in combination with all-trans-retinoic acid (ATRA) Relapsed/refractory acute promyelocytic leukaemia (APL)(Previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the promyelocytic leukaemia/retinoic-acid-receptor-alpha (PML/RAR-alpha) gene.The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined. | approved | Nov 14, 2019 | ema |
| Arsenic Trioxide | EU EMA | Acute Promyelocytic Leukemia | Trisenox is indicated for induction of remission, and consolidation in adult patients with: Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ? 10 x 103/µl) in combination with all?trans?retinoic acid (ATRA) Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene. The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined. | approved | Mar 5, 2002 | ema |
| Arsenic Trioxide | US FDA | Acute Promyelocytic Leukemia | In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. | approved | Sep 25, 2000 | openfda |
| Asciminib | EU EMA | Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive | Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP). Scemblix is indicated for the treatment of adult patients with Ph+ CML-CP with the T315I mutation who are resistant to, intolerant to or ineligible for ponatinib (see section 5.1). | approved | Aug 25, 2022 | ema |
| 102 |
| 3 |
| Sorafenib | 93 | 70 | 23 |
| Bosutinib | 91 | 32 | 59 |
| Imatinib Mesylate | 88 | 8 | 80 |
| Lapatinib | 85 | 64 | 21 |
| Palbociclib | 82 | 73 | 9 |
| Selumetinib | 82 | 68 | 14 |
| Cisplatin | 76 | 45 | 30 |
| Sunitinib | 76 | 59 | 16 |
| Nilotinib | 63 | 18 | 45 |
| Osimertinib | 62 | 48 | 14 |
| Chemotherapy | 61 | 39 | 22 |
| Larotrectinib | 59 | 52 | 7 |
| Axitinib | 57 | 17 | 40 |
| Entrectinib | 57 | 50 | 7 |
| Erdafitinib | 54 | 51 | 3 |
| Dactolisib | 53 | 44 | 9 |
| Pembrolizumab | 50 | 35 | 12 |
| Bevacizumab | 45 | 33 | 12 |
| Ponatinib | 45 | 39 | 6 |
| Irinotecan | 44 | 12 | 32 |
| Fluorouracil | 43 | 28 | 12 |
| Gemcitabine | 43 | 29 | 13 |
| Neratinib | 43 | 40 | 3 |
| Doxorubicin | 41 | 9 | 32 |
| Alectinib | 40 | 18 | 22 |
| Selpercatinib | 40 | 31 | 9 |
| Ceritinib | 38 | 25 | 13 |
| Everolimus | 38 | 34 | 4 |
| Venetoclax | 37 | 4 | 33 |
| Carboplatin | 36 | 28 | 8 |
| Fulvestrant | 35 | 30 | 5 |
| Vismodegib | 35 | 9 | 26 |
| Paclitaxel | 34 | 20 | 13 |
| Futibatinib | 32 | 29 | 3 |
| Midostaurin | 32 | 27 | 4 |
| Mercaptopurine | 31 | 2 | 28 |
| Rucaparib | 31 | 31 | 0 |
| Infigratinib | 30 | 26 | 4 |
| Docetaxel | 29 | 20 | 9 |
| Nivolumab | 29 | 20 | 6 |
| Thioguanine | 29 | 0 | 28 |
| Atezolizumab | 26 | 21 | 3 |
| Lorlatinib | 25 | 18 | 7 |
| Melphalan | 25 | 1 | 24 |
| Pazopanib | 25 | 24 | 1 |
| Pictilisib | 25 | 24 | 1 |
| Sirolimus | 25 | 20 | 5 |
| Pertuzumab | 24 | 24 | 0 |
| Trastuzumab Deruxtecan | 24 | 24 | 0 |
| Binimetinib | 23 | 22 | 1 |
| MDM2 Inhibitor AMGMDS3 | 23 | 1 | 22 |
| Regorafenib Anhydrous | 23 | 7 | 16 |
| Talazoparib | 23 | 23 | 0 |
| Tazemetostat | 23 | 23 | 0 |
| Temozolomide | 23 | 20 | 3 |
| Capivasertib | 22 | 21 | 1 |
| Oxaliplatin | 22 | 6 | 16 |
| Quizartinib | 22 | 13 | 8 |
| Gilteritinib | 21 | 18 | 3 |
| Alpelisib | 20 | 15 | 5 |
| BRAF Inhibitor | 20 | 20 | 0 |
| Brigatinib | 20 | 11 | 9 |
| Enzalutamide | 20 | 8 | 12 |
| Aspirin | 19 | 19 | 0 |
| Tamoxifen | 19 | 11 | 8 |
| Trastuzumab Emtansine | 19 | 10 | 9 |
| Cabozantinib | 18 | 17 | 1 |
| Capecitabine | 18 | 11 | 4 |
| Capmatinib | 18 | 15 | 1 |
| Sotorasib | 18 | 17 | 0 |
| Crenolanib | 17 | 16 | 1 |
| Cytarabine | 17 | 5 | 12 |
| Dacomitinib | 16 | 15 | 1 |
| Ivosidenib | 16 | 16 | 0 |
| Lestaurtinib | 16 | 15 | 1 |
| Mitogen-Activated Protein Kinase Kinase Inhibitor | 16 | 14 | 2 |
| Pemetrexed | 16 | 11 | 5 |
| PI103 | 16 | 16 | 0 |
| Temsirolimus | 16 | 15 | 1 |
| ALK Inhibitor TAE684 | 15 | 12 | 3 |
| Daunorubicin | 15 | 4 | 11 |
| Immune Checkpoint Inhibitor | 15 | 12 | 2 |
| Tepotinib | 15 | 15 | 0 |
| Abiraterone | 14 | 3 | 11 |
| Cobimetinib | 14 | 14 | 0 |
| Encorafenib | 14 | 13 | 1 |
| Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor | 14 | 10 | 4 |
| Methotrexate | 14 | 2 | 9 |
| Platinum Compound | 14 | 13 | 1 |
| Pralsetinib | 14 | 8 | 6 |
| Tretinoin | 14 | 8 | 6 |
| Bafetinib | 13 | 1 | 12 |
| Dovitinib | 13 | 13 | 0 |
| Pexidartinib | 13 | 5 | 8 |
| Ibrutinib | 12 | 6 | 6 |
| Prednisone | 12 | 12 | 0 |
| Ruxolitinib | 12 | 12 | 0 |
| Belvarafenib | 11 | 8 | 3 |
| Durvalumab | 11 | 10 | 1 |
| Mirdametinib | 11 | 9 | 2 |
| Revumenib | 11 | 4 | 7 |
| Akt Inhibitor MK2206 | 10 | 9 | 1 |
| Asparaginase | 10 | 0 | 10 |
| Etoposide | 10 | 7 | 3 |
| PD173074 | 10 | 10 | 0 |
| PLX4720 | 10 | 5 | 4 |
| R3Mab | 10 | 5 | 5 |
| Fexagratinib | 9 | 9 | 0 |
| JQ1 | 9 | 9 | 0 |
| PI3Ka/Di | 9 | 7 | 2 |
| Vandetanib | 9 | 8 | 1 |
| Inavolisib | 8 | 8 | 0 |
| Ipilimumab | 8 | 6 | 1 |
| MEK Inhibitor CI-1040 | 8 | 8 | 0 |
| Niraparib | 8 | 8 | 0 |
| Ribociclib | 8 | 5 | 3 |
| Vorinostat | 8 | 7 | 1 |
| Azacitidine | 7 | 7 | 0 |
| Foretinib | 7 | 6 | 1 |
| GSK126 | 7 | 7 | 0 |
| Mitomycin | 7 | 6 | 1 |
| MTOR Inhibitor | 7 | 7 | 0 |
| Multikinase Inhibitor AEE788 | 7 | 5 | 2 |
| Panobinostat | 7 | 6 | 1 |
| PI-103 | 7 | 5 | 2 |
| Repotrectinib | 7 | 7 | 0 |
| Sonidegib | 7 | 4 | 3 |
| Sunvozertinib | 7 | 7 | 0 |
| Taselisib | 7 | 6 | 1 |
| VTP-50469 | 7 | 0 | 7 |
| Arsenic Trioxide | 6 | 3 | 3 |
| AZD3463 | 6 | 1 | 5 |
| Dabrafenib/Trametinib Regimen | 6 | 6 | 0 |
| Dinaciclib | 6 | 5 | 1 |
| Ipilimumab/Nivolumab Regimen | 6 | 6 | 0 |
| Linsitinib | 6 | 6 | 0 |
| Pacritinib | 6 | 6 | 0 |
| Pan-RAF/MEK Molecular Glue NST-628 | 6 | 6 | 0 |
| Pemigatinib | 6 | 5 | 1 |
| Radiation Therapy | 6 | 4 | 2 |
| Tanespimycin | 6 | 6 | 0 |
| Trabectedin | 6 | 6 | 0 |
| Veliparib | 6 | 6 | 0 |
| Adavosertib | 5 | 5 | 0 |
| ALK Inhibitor ASP3026 | 5 | 1 | 4 |
| Amivantamab | 5 | 5 | 0 |
| Futuximab/Modotuximab Mixture | 5 | 5 | 0 |
| Hormone Therapy | 5 | 0 | 5 |
| MEK Inhibitor RO4987655 | 5 | 1 | 4 |
| Metformin | 5 | 5 | 0 |
| MTOR Kinase Inhibitor PP242 | 5 | 4 | 1 |
| PD1 Inhibitor | 5 | 4 | 1 |
| Regorafenib | 5 | 4 | 1 |
| Rociletinib | 5 | 4 | 1 |
| Sapanisertib | 5 | 5 | 0 |
| SU11274 | 5 | 5 | 0 |
| Abemaciclib | 4 | 4 | 0 |
| Anti-PD1 Monoclonal Antibody | 4 | 3 | 1 |
| Anti-PD-L1 Monoclonal Antibody | 4 | 2 | 2 |
| Apitolisib | 4 | 4 | 0 |
| Arabinosylguanine | 4 | 1 | 3 |
| ARS-1620 | 4 | 3 | 0 |
| Asciminib | 4 | 4 | 0 |
| Bicalutamide | 4 | 1 | 3 |
| Buparlisib | 4 | 4 | 0 |
| Decitabine | 4 | 4 | 0 |
| Dordaviprone | 4 | 4 | 0 |
| Duligotuzumab | 4 | 4 | 0 |
| Enasidenib | 4 | 4 | 0 |
| Eprenetapopt | 4 | 4 | 0 |
| Exemestane | 4 | 4 | 0 |
| FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 | 4 | 4 | 0 |
| FLT3 Tyrosine Kinase Inhibitor TTT-3002 | 4 | 4 | 0 |
| Icotinib | 4 | 3 | 1 |
| JQEZ5 | 4 | 4 | 0 |
| Lenvatinib | 4 | 3 | 1 |
| Letrozole | 4 | 3 | 1 |
| Leucovorin | 4 | 4 | 0 |
| Linifanib | 4 | 4 | 0 |
| MTOR Kinase Inhibitor AZD8055 | 4 | 2 | 2 |
| Nelarabine | 4 | 1 | 3 |
| Olutasidenib | 4 | 4 | 0 |
| Phosphatidylinositide 3-Kinase Inhibitor | 4 | 4 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 4 | 4 | 0 |
| PI3K/BET Inhibitor LY294002 | 4 | 4 | 0 |
| Poziotinib | 4 | 4 | 0 |
| Refametinib | 4 | 3 | 1 |
| Rogaratinib | 4 | 4 | 0 |
| Taxane Compound | 4 | 3 | 1 |
| Uprosertib | 4 | 4 | 0 |
| Vincristine | 4 | 3 | 1 |
| Vinorelbine | 4 | 4 | 0 |
| Vistusertib | 4 | 4 | 0 |
| Vorasidenib | 4 | 4 | 0 |
| Abiraterone Acetate | 3 | 0 | 3 |
| Adagrasib | 3 | 3 | 0 |
| AG1295 | 3 | 3 | 0 |
| Alisertib | 3 | 3 | 0 |
| Alvespimycin | 3 | 3 | 0 |
| Anti-CTLA-4 Monoclonal Antibody | 3 | 2 | 1 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| ATR Inhibitor | 3 | 3 | 0 |
| Avelumab | 3 | 2 | 1 |
| AZD-4547 | 3 | 3 | 0 |
| Birabresib | 3 | 3 | 0 |
| Bortezomib | 3 | 3 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 3 | 3 | 0 |
| Cabazitaxel | 3 | 2 | 1 |
| Canertinib | 3 | 3 | 0 |
| CDK Inhibitor SNS-032 | 3 | 3 | 0 |
| Cisplatin/Pembrolizumab/Pemetrexed Regimen | 3 | 0 | 3 |
| Deguelin | 3 | 3 | 0 |
| Dostarlimab | 3 | 3 | 0 |
| Dual IGF-1R/InsR Inhibitor BMS-754807 | 3 | 1 | 2 |
| EAP Protocol | 3 | 3 | 0 |
| Ensartinib | 3 | 3 | 0 |
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | 3 | 1 | 2 |
| FOLFOX-4 Regimen | 3 | 0 | 3 |
| IGF1R Monoclonal Antibody | 3 | 3 | 0 |
| Immunotherapy | 3 | 3 | 0 |
| Ipatasertib | 3 | 3 | 0 |
| KRAS G12D Inhibitor HRS-4642 | 3 | 3 | 0 |
| KW2449 | 3 | 3 | 0 |
| Lazertinib | 3 | 3 | 0 |
| Letetresgene Autoleucel | 3 | 3 | 0 |
| Lucitanib | 3 | 3 | 0 |
| Mobocertinib | 3 | 3 | 0 |
| PD98059 | 3 | 1 | 2 |
| Perifosine | 3 | 3 | 0 |
| Prednisolone | 3 | 0 | 3 |
| R406 | 3 | 3 | 0 |
| Ramucirumab | 3 | 2 | 1 |
| RapaLink-1 | 3 | 1 | 2 |
| RDEA 119 | 3 | 3 | 0 |
| RG7112 | 3 | 2 | 1 |
| Ridaforolimus | 3 | 2 | 1 |
| Savolitinib | 3 | 2 | 1 |
| SU5614 | 3 | 0 | 3 |
| Tandutinib | 3 | 2 | 1 |
| Tegafur | 3 | 0 | 0 |
| Teprotumumab | 3 | 3 | 0 |
| Tremelimumab | 3 | 3 | 0 |
| Trichostatin A | 3 | 2 | 1 |
| Zongertinib | 3 | 3 | 0 |
| 5-Fluorouracil/Salicylic Acid Topical Solution | 2 | 0 | 2 |
| 7-Ethyl-10-Hydroxycamptothecin | 2 | 2 | 0 |
| Adjuvant Chemotherapy | 2 | 2 | 0 |
| AGI-5198 | 2 | 2 | 0 |
| AGS324 | 2 | 2 | 0 |
| ALK2 Inhibitor LDN-193189 | 2 | 2 | 0 |
| Alvocidib | 2 | 2 | 0 |
| Amrubicin | 2 | 1 | 1 |
| Angiogenesis Inhibitor | 2 | 2 | 0 |
| Anti-CD33 | 2 | 2 | 0 |
| Anti-ErbB3 Monoclonal Antibody AV-203 | 2 | 2 | 0 |
| Anti-PD-1 Monoclonal Antibody MEDI0680 | 2 | 2 | 0 |
| Aromatase Inhibitor | 2 | 1 | 1 |
| Aumolertinib | 2 | 1 | 1 |
| Bazedoxifene | 2 | 1 | 1 |
| Belinostat | 2 | 0 | 0 |
| BET Inhibitor | 2 | 2 | 0 |
| Camonsertib | 2 | 2 | 0 |
| Carboplatin/Paclitaxel Regimen | 2 | 2 | 0 |
| Carboplatin/Pemetrexed Regimen | 2 | 2 | 0 |
| CDK4/6 Inhibition | 2 | 1 | 1 |
| Cediranib | 2 | 2 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 2 | 2 | 0 |
| Chk1 Inhibitor | 2 | 2 | 0 |
| Copanlisib | 2 | 2 | 0 |
| Derazantinib | 2 | 2 | 0 |
| Durvalumab/Tremelimumab Regimen | 2 | 2 | 0 |
| EPZ011989 | 2 | 2 | 0 |
| Firmonertinib | 2 | 2 | 0 |
| FLT3 Inhibitor FF-10101 Succinate | 2 | 2 | 0 |
| FOLFIRI Regimen | 2 | 2 | 0 |
| Ganetespib | 2 | 1 | 1 |
| Ganitumab | 2 | 2 | 0 |
| Hematopoietic Cell Transplantation | 2 | 2 | 0 |
| Imlunestrant Regimen | 2 | 2 | 0 |
| Irbesartan | 2 | 2 | 0 |
| Izorlisib | 2 | 2 | 0 |
| JQ-1 | 2 | 2 | 0 |
| JSI-124 | 2 | 2 | 0 |
| L19IL2 | 2 | 2 | 0 |
| Levoleucovorin | 2 | 1 | 1 |
| Lometrexol | 2 | 2 | 0 |
| Lomustine | 2 | 2 | 0 |
| Lunresertib | 2 | 2 | 0 |
| Masitinib | 2 | 1 | 1 |
| Mocetinostat | 2 | 2 | 0 |
| Motesanib | 2 | 0 | 2 |
| Nab-paclitaxel | 2 | 1 | 1 |
| Navtemadlin | 2 | 2 | 0 |
| Nimotuzumab | 2 | 2 | 0 |
| NSC348884 | 2 | 2 | 0 |
| NSC84167 | 2 | 2 | 0 |
| Omacetaxine Mepesuccinate | 2 | 2 | 0 |
| Palbociclib Regimen | 2 | 2 | 0 |
| Pan-AKT Kinase Inhibitor GSK690693 | 2 | 1 | 1 |
| PD-1 Ligand Inhibitor | 2 | 1 | 1 |
| Pidnarulex | 2 | 2 | 0 |
| Prexasertib | 2 | 2 | 0 |
| Quarfloxin | 2 | 2 | 0 |
| R-CHOP Regimen | 2 | 1 | 1 |
| Rebemadlin | 2 | 1 | 1 |
| Retaspimycin Hydrochloride | 2 | 2 | 0 |
| Rezatapopt | 2 | 2 | 0 |
| RG7356 | 2 | 1 | 1 |
| Rigosertib | 2 | 0 | 2 |
| Rovalpituzumab Tesirine | 2 | 2 | 0 |
| Sacituzumab Govitecan | 2 | 0 | 2 |
| SAIT301 | 2 | 2 | 0 |
| Salinomycin | 2 | 2 | 0 |
| Salirasib | 2 | 2 | 0 |
| Selective Estrogen Receptor Covalent Antagonist H3B-6545 | 2 | 2 | 0 |
| Setidegrasib | 2 | 2 | 0 |
| Sevabertinib | 2 | 2 | 0 |
| Sintilimab | 2 | 2 | 0 |
| Sotrastaurin Acetate | 2 | 2 | 0 |
| Spliceostatin A | 2 | 2 | 0 |
| Sulindac | 2 | 2 | 0 |
| Taletrectinib | 2 | 2 | 0 |
| Tarextumab | 2 | 2 | 0 |
| Therapeutic Tumor Infiltrating Lymphocytes | 2 | 1 | 1 |
| Tipifarnib | 2 | 2 | 0 |
| Tovorafenib | 2 | 2 | 0 |
| Trastuzumab Deruxtecan | 2 | 2 | 0 |
| Triciribine | 2 | 2 | 0 |
| Tucatinib | 2 | 2 | 0 |
| Tyrosine Kinase Inhibitor | 2 | 2 | 0 |
| Tyrphostin AG 1296 | 2 | 2 | 0 |
| U0126 | 2 | 0 | 2 |
| Valproic Acid | 2 | 2 | 0 |
| Vatalanib | 2 | 2 | 0 |
| Verteporfin | 2 | 2 | 0 |
| Zenocutuzumab-zbco | 2 | 2 | 0 |
| Ziftomenib | 2 | 2 | 0 |
| Zolbetuximab | 2 | 2 | 0 |
| 2,4-pyrimidinediamine | 1 | 1 | 0 |
| 2-Deoxy-D-glucose | 1 | 1 | 0 |
| 3-Dimensional Conformal Radiation Therapy | 1 | 1 | 0 |
| 4'-(9-acridinylamino)methanesulfon-m-anisidide | 1 | 0 | 1 |
| 5-Fluoro-2-Deoxycytidine | 1 | 1 | 0 |
| 6-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl)-N-(4-(methylsulfonyl)phenyl)pyridin-2-amine | 1 | 1 | 0 |
| 9F7-F11 | 1 | 1 | 0 |
| A66 | 1 | 1 | 0 |
| Abemaciclib Regimen | 1 | 1 | 0 |
| Abexinostat | 1 | 1 | 0 |
| ACLY SiRNA | 1 | 1 | 0 |
| Adebrelimab | 1 | 1 | 0 |
| Ado-trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| Afamitresgene Autoleucel | 1 | 1 | 0 |
| Afimoxifene | 1 | 0 | 1 |
| Agerafenib | 1 | 1 | 0 |
| AKTi-1/2 | 1 | 1 | 0 |
| Alemtuzumab | 1 | 1 | 0 |
| ALK/TRK Inhibitor TSR-011 | 1 | 0 | 1 |
| AMG511 | 1 | 1 | 0 |
| Aminoglutethimide | 1 | 1 | 0 |
| Amphotericin B | 1 | 1 | 0 |
| Amuvatinib | 1 | 1 | 0 |
| Anthracycline Antineoplastic Antibiotic | 1 | 0 | 1 |
| Anti-CD123 | 1 | 1 | 0 |
| Anti-EGFR Monoclonal Antibody | 1 | 0 | 1 |
| Antigen-specific Cytotoxic T-lymphocyte Therapy | 1 | 1 | 0 |
| Anti-PDL1 Therapy | 1 | 1 | 0 |
| Antisecretory Factor-enriched Egg Yolk Powder Supplement | 1 | 1 | 0 |
| Anti-TIM-3 Monoclonal Antibody | 1 | 1 | 0 |
| Apalutamide | 1 | 0 | 1 |
| ARQ092 | 1 | 1 | 0 |
| ARS-853 | 1 | 1 | 0 |
| AS602868 | 1 | 1 | 0 |
| Aurora A Kinase Inhibitor LY3295668 Erbumine | 1 | 1 | 0 |
| Avutometinib And Defactinib | 1 | 1 | 0 |
| AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M | 1 | 1 | 0 |
| AZ20 | 1 | 1 | 0 |
| AZ628 | 1 | 1 | 0 |
| AZ909 | 1 | 1 | 0 |
| Azathioprine | 1 | 0 | 0 |
| AZD5438 | 1 | 1 | 0 |
| Barasertib | 1 | 1 | 0 |
| BCR-ABL Inhibitor HS-10382 | 1 | 1 | 0 |
| Befotertinib | 1 | 1 | 0 |
| Berzosertib | 1 | 1 | 0 |
| Bevacizumab/Lomustine Regimen | 1 | 1 | 0 |
| Bimiralisib | 1 | 1 | 0 |
| BMVC-8C3O | 1 | 1 | 0 |
| Bone Marrow Transplantation | 1 | 1 | 0 |
| BPTES | 1 | 1 | 0 |
| C646 | 1 | 1 | 0 |
| Camptothecin | 1 | 1 | 0 |
| Camrelizumab | 1 | 1 | 0 |
| CAN508 | 1 | 1 | 0 |
| CAPOX Regimen | 1 | 1 | 0 |
| Carboplatin OR Cisplatin | 1 | 0 | 1 |
| Carfilzomib | 1 | 1 | 0 |
| Carmustine | 1 | 1 | 0 |
| C-DIM 12 | 1 | 0 | 1 |
| Celecoxib | 1 | 1 | 0 |
| Cetuximab/Encorafenib Regimen | 1 | 1 | 0 |
| Cetuximab/Irinotecan Regimen | 1 | 0 | 1 |
| CH6953755 | 1 | 1 | 0 |
| CH7233163 | 1 | 1 | 0 |
| Chemoimmunotherapy | 1 | 0 | 1 |
| Chemoradiotherapy | 1 | 0 | 1 |
| Chlorambucil | 1 | 1 | 0 |
| Chloroquine | 1 | 1 | 0 |
| CHZ868 | 1 | 1 | 0 |
| Cixutumumab | 1 | 1 | 0 |
| C-Met Inhibitor | 1 | 1 | 0 |
| Conatumumab | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Cyclophosphamide | 1 | 1 | 0 |
| Cyproterone Acetate | 1 | 0 | 1 |
| Dacarbazine | 1 | 1 | 0 |
| Dacomitinib | 1 | 1 | 0 |
| Daromun | 1 | 1 | 0 |
| Datopotamab Deruxtecan | 1 | 1 | 0 |
| Datopotamab Deruxtecan Regimen | 1 | 1 | 0 |
| Dexamethasone | 1 | 1 | 0 |
| Disitamab Vedotin | 1 | 1 | 0 |
| Divarasib | 1 | 1 | 0 |
| Donor Lymphocyte Infusion | 1 | 1 | 0 |
| DS-6501b | 1 | 1 | 0 |
| Durvalumab Regimen | 1 | 1 | 0 |
| DVP Regimen | 1 | 0 | 1 |
| EFTX-G12V | 1 | 1 | 0 |
| EGFR Tyrosine Kinase Inhibitor Therapy | 1 | 1 | 0 |
| Elacestrant | 1 | 1 | 0 |
| Elimusertib | 1 | 1 | 0 |
| Endocrine Drug Therapy | 1 | 1 | 0 |
| Enfortumab Vedotin | 1 | 1 | 0 |
| Enzastaurin | 1 | 1 | 0 |
| Epirubicin | 1 | 1 | 0 |
| EPZ004777 | 1 | 1 | 0 |
| ERBB3 Inhibitor | 1 | 1 | 0 |
| Erdafitinib Regimen | 1 | 1 | 0 |
| Eribulin | 1 | 1 | 0 |
| Erlotinib Hydrochloride | 1 | 1 | 0 |
| Everolimus/Exemestane Regimen | 1 | 1 | 0 |
| EZH2 Inhibitor | 1 | 1 | 0 |
| FAC Regimen | 1 | 0 | 1 |
| FACT Complex-targeting Curaxin CBL0137 | 1 | 1 | 0 |
| Fadraciclib | 1 | 1 | 0 |
| Fasudil | 1 | 1 | 0 |
| FEC Regimen | 1 | 0 | 1 |
| Fedratinib | 1 | 1 | 0 |
| FGFR4 Inhibitor H3B-6527 | 1 | 1 | 0 |
| FGFR Inhibitor ASP5878 | 1 | 1 | 0 |
| Fisogatinib | 1 | 1 | 0 |
| Fludarabine | 1 | 1 | 0 |
| Flutamide | 1 | 0 | 1 |
| FOLFIRI-Panitumumab Regimen | 1 | 0 | 1 |
| FOLFOX-6 Regimen | 1 | 1 | 0 |
| FOLFOX Regimen | 1 | 1 | 0 |
| G007-LK | 1 | 1 | 0 |
| G-573 | 1 | 1 | 0 |
| Galeterone | 1 | 1 | 0 |
| Galiximab | 1 | 1 | 0 |
| GDC-0879 | 1 | 1 | 0 |
| Gemtuzumab Ozogamicin | 1 | 1 | 0 |
| GF109203X | 1 | 1 | 0 |
| GNE-617 | 1 | 1 | 0 |
| Go6983 | 1 | 1 | 0 |
| GPI-15427 | 1 | 1 | 0 |
| G-Quadruplex Stabilizer BMVC | 1 | 1 | 0 |
| GSK321 | 1 | 1 | 0 |
| Guadecitabine | 1 | 1 | 0 |
| GW-2580 | 1 | 1 | 0 |
| HCI-2509 | 1 | 1 | 0 |
| HDAC Inhibitor OBP-801 | 1 | 1 | 0 |
| HDAC Inhibitor REC-2282 | 1 | 1 | 0 |
| HDM2 Inhibitor MK-8242 | 1 | 1 | 0 |
| HER2 Inhibitor CP-724,714 | 1 | 0 | 1 |
| Hydroxychloroquine | 1 | 1 | 0 |
| HyperCVAD Regimen | 1 | 1 | 0 |
| I-BET151 | 1 | 1 | 0 |
| Ibuprofen | 1 | 1 | 0 |
| ICX-101 | 1 | 1 | 0 |
| Idarubicin | 1 | 1 | 0 |
| Idelalisib | 1 | 1 | 0 |
| IMG-2005-5 | 1 | 1 | 0 |
| Immunomodulatory Oligonucleotide | 1 | 1 | 0 |
| Inhibitor | 1 | 1 | 0 |
| Iniparib | 1 | 1 | 0 |
| Interventional Radiology Procedure | 1 | 1 | 0 |
| Iodine I-131 | 1 | 0 | 1 |
| Ionizing Radiotherapy | 1 | 0 | 1 |
| IRAK-1/4 Inhibitor | 1 | 1 | 0 |
| Ixazomib | 1 | 0 | 1 |
| JAK2 Inhibitor AZD1480 | 1 | 1 | 0 |
| JAK Inhibitor I | 1 | 1 | 0 |
| JNJ38877605 | 1 | 0 | 1 |
| JQ1 Compound | 1 | 1 | 0 |
| JW55 | 1 | 1 | 0 |
| K 252a | 1 | 0 | 1 |
| KG5 | 1 | 0 | 1 |
| KU-0060648 | 1 | 1 | 0 |
| Lasofoxifene | 1 | 1 | 0 |
| Lenalidomide | 1 | 0 | 1 |
| Leuprolide | 1 | 1 | 0 |
| Lonafarnib | 1 | 0 | 1 |
| Luminespib | 1 | 0 | 1 |
| Lumretuzumab | 1 | 1 | 0 |
| Lysine | 1 | 0 | 1 |
| MAP855 | 1 | 1 | 0 |
| Margetuximab | 1 | 1 | 0 |
| Mcl-1 Inhibitor MIK665 | 1 | 1 | 0 |
| MEK-1/MEKK-1 Inhibitor E6201 | 1 | 1 | 0 |
| MEK Inhibitor GDC-0623 | 1 | 1 | 0 |
| MEK Inhibitor REC-4881 | 1 | 1 | 0 |
| Menin Inhibitor | 1 | 1 | 0 |
| MET Tyrosine Kinase Inhibitor SGX523 | 1 | 1 | 0 |
| Molibresib | 1 | 1 | 0 |
| Monomethyl Auristatin E | 1 | 0 | 1 |
| MUC1-targeted Peptide GO-203-2C | 1 | 0 | 1 |
| Multi-subtype Natural Human Leukocyte Interferon Alpha | 1 | 0 | 1 |
| MVT Regimen | 1 | 0 | 1 |
| Nano TACs | 1 | 1 | 0 |
| Naquotinib | 1 | 0 | 1 |
| NCT00137111 | 1 | 1 | 0 |
| Nedaplatin | 1 | 0 | 1 |
| Niacinamide | 1 | 0 | 1 |
| Nilutamide | 1 | 0 | 1 |
| Ningetinib | 1 | 1 | 0 |
| Nintedanib | 1 | 1 | 0 |
| Nirogacestat | 1 | 1 | 0 |
| Not Applicable | 1 | 0 | 0 |
| NOTCH1 Antibody (PF-06293622) | 1 | 1 | 0 |
| NU7441 | 1 | 1 | 0 |
| Nutlin-3 | 1 | 1 | 0 |
| NVP-AEW541 | 1 | 1 | 0 |
| NVP-AST487 | 1 | 1 | 0 |
| O6-Benzylguanine | 1 | 1 | 0 |
| OICR-9429 | 1 | 1 | 0 |
| Omipalisib | 1 | 1 | 0 |
| Onalespib | 1 | 1 | 0 |
| Onartuzumab | 1 | 1 | 0 |
| Onatasertib | 1 | 1 | 0 |
| Osimertinib Mesylate | 1 | 1 | 0 |
| Paclitaxel Liposome | 1 | 1 | 0 |
| Palliative Radiation Therapy | 1 | 0 | 1 |
| Panitumumab Regimen | 1 | 1 | 0 |
| Pan-Mutant-IDH1 Inhibitor Bay-1436032 | 1 | 1 | 0 |
| Pan-RAF Inhibitor LY3009120 | 1 | 1 | 0 |
| PARP Inhibitor ABT-888 | 1 | 1 | 0 |
| PARP Inhibitor AZD2461 | 1 | 1 | 0 |
| Pasireotide | 1 | 1 | 0 |
| Patidegib | 1 | 1 | 0 |
| Patritumab | 1 | 1 | 0 |
| Patritumab Deruxtecan | 1 | 1 | 0 |
| PCV Regimen | 1 | 1 | 0 |
| PD-180970 | 1 | 1 | 0 |
| PD-L1 Inhibitor | 1 | 1 | 0 |
| Pegargiminase | 1 | 1 | 0 |
| Peginterferon Alfa-2a | 1 | 1 | 0 |
| Peginterferon Alfa-2b | 1 | 1 | 0 |
| Pembrolizumab/Pemetrexed Regimen | 1 | 1 | 0 |
| Pemrametostat | 1 | 1 | 0 |
| Pertuzumab/Trastuzumab Regimen | 1 | 0 | 1 |
| PHA-665752 | 1 | 0 | 1 |
| Picoplatin | 1 | 0 | 1 |
| Pictilisib Bismesylate | 1 | 1 | 0 |
| Pilaralisib | 1 | 1 | 0 |
| Pixantrone | 1 | 0 | 1 |
| Platinum Doublet | 1 | 0 | 1 |
| Pomalidomide | 1 | 0 | 1 |
| Porcupine Inhibitor WNT974 | 1 | 1 | 0 |
| PSI | 1 | 1 | 0 |
| Pyridostatin | 1 | 1 | 0 |
| Pyrimidine Antagonist | 1 | 1 | 0 |
| Pyrotinib | 1 | 1 | 0 |
| Quisinostat | 1 | 1 | 0 |
| Radioactive Iodine | 1 | 1 | 0 |
| Raltitrexed | 1 | 0 | 1 |
| RG5 | 1 | 0 | 1 |
| Rilotumumab | 1 | 1 | 0 |
| Rindopepimut | 1 | 1 | 0 |
| RMC-4550 | 1 | 1 | 0 |
| Roflumilast | 1 | 1 | 0 |
| Safusidenib | 1 | 1 | 0 |
| Samotolisib | 1 | 1 | 0 |
| SB202190 | 1 | 1 | 0 |
| SCH772984 | 1 | 1 | 0 |
| Selinexor | 1 | 0 | 1 |
| Seribantumab | 1 | 1 | 0 |
| Sertraline | 1 | 1 | 0 |
| SGK1-Inh | 1 | 1 | 0 |
| SHP2 Inhibitor | 1 | 1 | 0 |
| Stattic | 1 | 1 | 0 |
| Staurosporine | 1 | 1 | 0 |
| TAK-788 | 1 | 1 | 0 |
| Tamibarotene | 1 | 0 | 1 |
| Tarloxotinib | 1 | 1 | 0 |
| Taxol | 1 | 0 | 1 |
| Telmisartan | 1 | 1 | 0 |
| Tgx 221 | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Therapeutic Glucocorticoid | 1 | 0 | 1 |
| Tirbanibulin | 1 | 1 | 0 |
| Tisagenlecleucel | 1 | 0 | 1 |
| Tislelizumab | 1 | 1 | 0 |
| Tizaterkib | 1 | 1 | 0 |
| Tofacitinib | 1 | 1 | 0 |
| Topotecan | 1 | 1 | 0 |
| Toripalimab | 1 | 1 | 0 |
| Tozasertib | 1 | 1 | 0 |
| Tranilast | 1 | 1 | 0 |
| Trastuzumab Deruxtecan Regimen | 1 | 1 | 0 |
| Trastuzumab Emtansine Regimen | 1 | 1 | 0 |
| TRK Inhibitor | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| Tyrphostin AG 1295 | 1 | 1 | 0 |
| Tyrphostin AG 1478 | 1 | 1 | 0 |
| UNC1062 | 1 | 1 | 0 |
| UNC1999 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| VE-821 | 1 | 1 | 0 |
| VEGF/VEGFR Inhibitors | 1 | 1 | 0 |
| Vociprotafib | 1 | 0 | 0 |
| Volasertib | 1 | 1 | 0 |
| VTP50469 | 1 | 1 | 0 |
| VTX-11e | 1 | 1 | 0 |
| WHI-P154 | 1 | 1 | 0 |
| WRN Inhibitor HRO761 | 1 | 1 | 0 |
| WRN Inhibitor RO7589831 | 1 | 1 | 0 |
| WYE354 | 1 | 0 | 1 |
| WZ4002 | 1 | 0 | 1 |
| Zoledronic Acid | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.